How consistent is compounded topical atropine from bottle-to-bottle? What clinical results could indicate variability? Read more in this clinical case where a miniscule change in concentration gave notably better clinical outcomes.
During the COVID-19 pandemic, governments imposed home confinement and school-based learning was the normal. Has this caused more myopia? In this clinical case, the unique environment of lockdown is explored in view of myopia management outcomes.
What amount of axial length growth be expected in myopes versus emmetropes, and how can you tell if your myopia control treatment is working? This important clinical reference provides all this information and more on axial growth in younger and older children, emmetropes and myopes, and even data on typical myopia stabilization.
Children, teens and adults with high myopia need special consideration of not just myopia control, but the best type of myopia correction and the importance of ocular health management. Do high myopes progress more quickly? What are the risks and management options?
Growth charts are commonly used in childhood health and are easily understood by parents. When applied to myopia management, axial length growth charts can allow individualized decisions on treatment strategy and efficacy. What charts are available now and how can you use them in practice? Here we explain how to use axial length growth charts from initial diagnosis to treatment strategy and long term monitoring.
When setting myopia control expectations both at outset and follow up, it is important to compare the child’s observed myopia progression to ‘average’, and to then judge the expected outcomes of treatment. Bringing their lifestyle, motivations and abilities into consideration is also important. Here we explore how to use resources in practice to set expectations and gauge success along the way.
What do you do when your patient doesn’t respond to your orthokeratology (orthoK) treatment and things don’t add up? Here’s a case for you where an optometrist had to become a bit more investigative to determine the cause.
What do you do when your patient doesn’t respond to your low-dose atropine treatment? This case explores the nuances in navigating management when atropine doesn’t work as well as you might expect.
Non-responders are those children who have shown minimal efficacy of their treatment in myopia control studies, and it turns out that there’s around 15-20% of children who are classified this way across the major myopia control intervention studies. We look at non-responders in atropine, multifocal and myopia controlling contact lens, orthokeratology and DIMS spectacle lens studies, and what factors non-responders share across these studies.
When myopia progression seems to be faster than expected for a myopia control treatment, various factors can be at play, such as non-compliance, user error, high myopia, binocular vision, visual environment. Or you may have a non-responder on your hands. What should you do? Read more here.
